Rohit Thummalapalli
@rohit_thum
Followers
723
Following
3K
Media
58
Statuses
942
GI medical oncologist @MSKCancerCenter focused on neuroendocrine and hepatobiliary cancers. Prior @oslerresidency @harvardmed @yale.
New York, NY
Joined July 2010
Tinengotinib for adults with advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 trial - The Lancet Gastroenterology & Hepatology @JavleMilind @OncoAlert
thelancet.com
These findings suggest that tinengotinib might have activity in patients with cholangiocarcinoma with FGFR2 fusions that progressed following FGFR inhibitor therapy. Anti-tumour activity was also...
0
7
18
A breakthrough moment in high-grade neuroendocrine oncology. 🔬 This new @JCOPO_ASCO analysis positions DLL3 as one of the most compelling biomarkers in aggressive GEP-NEN biology. @OncoAlert @ASCO
https://t.co/h82LULUw02
2
19
41
Wow, fantastic paper! DLL3 expression in high grade GEP NET !!
(1/X) Excited to share our work describing clinicopathologic correlates of DLL3 expression and functional imaging in patients with GEP NECs and high grade GEP NETs - out today in @JCOPO_ASCO. https://t.co/w09fZbustH
0
2
6
DLL3 in GEP-NENs: new therapeutic window 🔥 High DLL3 expression: 71% GEP-NECs, 40% G3 NETs, esp. PanNET G3 (43%) ⚠️ DLL3+ G3 PanNETs → worse survival (HR 3.27) 🧪 DLL3-immunoPET detected avid lesions in 5/6 patients 💡DLL3: promising target for NEC & high-grade PanNETs 🔗
0
7
14
Landmark paper from @MSKCancerCenter led by my friend @rohit_thum on landscape of DLL3 in GEP Neuroendocrine neoplasms. DLL3 is not prognostic, enriched in small cell histology and can be found in 40% of well diff G3 NENs! Functional imaging offers a promising platform for DLL3
1
7
24
#DLL3 #NET @rohit_thum @DianeReidyLagun @MSK_DeptOfMed important target in GI, looking forward to seeing more in this space! https://t.co/22yDvtF923
ascopubs.org
PURPOSEDelta-like ligand 3 (DLL3) is an emerging target across neuroendocrine cancers, but remains underexplored in gastroenteropancreatic neuroendocrine neoplasms (GEP NENs), including poorly...
0
7
22
@JCOPO_ASCO I want to extend a big thank you to all who supported this work – more to come from our group! @DianeReidyLagun @Tendler_S @lisabodei @LewisLabMSKCC @NANETS1 @NCFCancer and many others not on Twitter
0
0
1
@JCOPO_ASCO (5/X) We think this work could help inform further DLL3 therapeutic development in GEP NENs – notably highlighting G3 GEP NET population which have to date generally been excluded from clinical trials of novel agents in this space.
1
0
1
@JCOPO_ASCO (4/X) We next performed 89Zr-SC16.56 functional DLL3 immunoPET-CT imaging in patients with DLL3 IHC-positive disease, describing high level functional DLL3 tumor avidity both in patients with GEP NECs (left) and G3 well differentiated pancreatic NETs (right).
1
2
2
@JCOPO_ASCO (3/X) Among well differentiated GEP NETs, we describe DLL3 expression in ~40% of high grade (G3) tumors, most commonly G3 pancreatic NETs, and describe association of DLL3 expression and poor outcomes with standard therapies in pancreatic NETs.
1
1
3
@JCOPO_ASCO (2/X) First, we describe DLL3 IHC expression in ~70% of poorly differentiated GEP NECs across primary sites of disease, with enrichment for small cell histology, supporting multiple ongoing therapeutic efforts in this space.
1
0
1
(1/X) Excited to share our work describing clinicopathologic correlates of DLL3 expression and functional imaging in patients with GEP NECs and high grade GEP NETs - out today in @JCOPO_ASCO. https://t.co/w09fZbustH
ascopubs.org
PURPOSEDelta-like ligand 3 (DLL3) is an emerging target across neuroendocrine cancers, but remains underexplored in gastroenteropancreatic neuroendocrine neoplasms (GEP NENs), including poorly...
1
5
18
These findings are very interesting and we couldn’t have contributed Mayo data with out you, Osama. There seems to be activity of ICI after progression of panc NETs following prior alkylating therapy but the benefit may be limited to those with high TMB and/or dMMR.
Grateful to contribute to this multi-institutional study. Our study shows that immunotherapy may be effective in metastatic pancreatic NETs pretreated with alkylating agents with dMMR or TMB-high status. Our findings support NGS testing and assessing MMR and TMB status following
0
1
12
We looked at this exact question and found that high TMB after targeted therapy, which is more striking in plasma than in tissue, is not sufficient to engender a response to immunotherapy. Manuscript just out!
High-TMB after anti-EGFR therapy in MSS CRC @ESMO_Open ✅TMB ≥10 (after vs before anti-EGFR): 33.8% vs 9.7% ✅Higher alterations of MAPK signaling 👉Could high-TMB accompanied by "subclonal" alterations after anti-EGFR therapy be a target for immunotherapy?
3
15
58
Fits with our experience. TMB-H responses generally restricted to dMMR/MSI-H or POLE/D-mut tumors.
nejm.org
The FDA has approved immune checkpoint inhibitors for solid tumors of any histologic origin with more than 10 mutations per megabase of DNA. This study showed that in tumors with high mutational ...
Our former colleague, Dr. Nakamura, presented a phase 2 study of nivolumab for plasma TMB-H GI cancers at #GI24 ✅Response in 3 of 27 CRC with pTMB-H ✅Breakdown of the 3 responders: MSI-H (1), POLE (2) 👉No responders in remaining 24 CRC with pTMB-H https://t.co/HSA1akJkBh
0
3
14
📗Adrenocortical carcinoma: a practical guide for clinicians @TheLancetEndo ✅Very nice source for practice ✅Diagnosis, treatment algorithm, systemic treatment, mitotan management 👉 https://t.co/oINY7d6BTJ
#cancer #oncology #MedX @OncoAlert
6
60
135
Gocatamig looking very active in SCLC and NEC. Space is getting crowded quickly which is great for our patients!
🆙#ESMO25🇩🇪 🔥#LCSM Mini Oral, non-mets, SCLC ☑️Updated results from a phase I/II study of gocatamig for small cell lung cancer (SCLC) and other neuroendocrine cancers ☑️ORR 44%, DCR 66% 🎙️ Dr. Himisha Beltran @OncoAlert @myESMO @Larvol
0
0
5
Please tune in to this amazing podcast on everything DLL3 and beyond by the very talented @rohit_thum of @MSKCancerCenter @NCFCancer @lisayentwin @NANETS1 @ENETS_ORG
Really enjoyed catching up w/ @lisayentwin and @NCFCancer on our ongoing work on DLL3 targeting in gastrointestinal/pancreatic neuroendocrine cancers and the exciting drug development landscape across therapeutic classes in this space! @NANETS1 #NANETS25
https://t.co/QiWNSRUPOz
1
3
9
Really enjoyed catching up w/ @lisayentwin and @NCFCancer on our ongoing work on DLL3 targeting in gastrointestinal/pancreatic neuroendocrine cancers and the exciting drug development landscape across therapeutic classes in this space! @NANETS1 #NANETS25
https://t.co/QiWNSRUPOz
ncf.net
0
2
7